iShares Russell 2000 ETF vs Stryker Corporation — how do they compare? iShares Russell 2000 ETF trades at $279.36 (market cap $77.70B), while Stryker Corporation trades at $277.57 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays a 1.27% dividend while iShares Russell 2000 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Stryker Corporation for 21 Days on average.
| IWM | SYK | |
|---|---|---|
Market Cap | $77.70B | $106.24B |
Volume | 35,598,983 | 2,982,001 |
52-Week High | $305.06 | $388.35 |
52-Week Low | $229.13 | $269.75 |
Typical Hold Time | 83 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $279.1, up 0.5% on the day. Technical indicators are predominantly bearish, with moving averages and ADX signaling a downtrend, though oscillators like RSI are neutral. The fund lacks traditional valuation ratios as it is an ETF, and recent news highlights its underperformance versus the S&P 500 over the past decade, with concerns about its inclusion of unprofitable companies.
The outlook for IWM is clouded by persistent underperformance and sensitivity to interest rate hikes, which pressure small caps. While offering diversification away from large-cap tech, the fund faces headwinds from economic tightening and narrow market breadth. A rebound hinges on broader market participation and favorable macroeconomic conditions, but near-term risks remain elevated.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →